On Tuesday, September 11, analysts at Goldman Sachs upgraded shares of Bristol-Myers Squibb Co. (BMY). Goldman Sachs reiterated its Buy rating on the stock and set a $40.00/share price target. An analyst upgrade or reiteration can mean great things for a stock, and in the wake of Goldman Sachs reiteration, which took place today, I wanted to highlight some of the positive catalysts behind my decision to establish a position in Bristol-Myers Squibb.

Overview

Bristol-Myers Squibb Co., which is based in New York, New York, is a biopharmaceutical company, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include PLAVIX for protection against fatal or non-fatal heart attack or stroke; AVAPRO/AVALIDE for the treatment of hypertension and diabetic nephropathy; ELIQUIS to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; ABILIFY, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and REYATAZ for the treatment of HIV. The company's principal products also comprise SUSTIVA for the treatment of HIV; BARACLUDE, an inhibitor of hepatitis B virus; ERBITUX to target and block the epidermal growth factor receptor; SPRYCEL for treatment of chronic myeloid leukemia in adults; YERVOY to treat metastatic melanoma; ORENCIA to treat moderate to severe rheumatoid arthritis in adults; NULOJIX to prevent solid organ transplant rejection; and ONGLYZA for the treatment of type 2 diabetes.

READ FULL ARTICLE HERE...